Mobile

A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Sym...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-001451-19

A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the efficacy of YM178 50 mg qd and YM178 100 mg qd against placebo in the treatment of subjects with symptoms of overactive bladder.

Critère d'inclusion

  • Symptoms of Overactive Bladder

Liens